Transamerica Financial Advisors LLC Sells 635 Shares of Johnson & Johnson $JNJ

Transamerica Financial Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,569 shares of the company’s stock after selling 635 shares during the period. Transamerica Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,753,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Elios Financial Group Inc. raised its stake in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC grew its holdings in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after acquiring an additional 67 shares during the period. MBA Advisors LLC raised its position in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares in the last quarter. Sovereign Financial Group Inc. lifted its stake in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.

Johnson & Johnson Trading Down 1.0%

NYSE:JNJ opened at $176.63 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The firm has a 50-day moving average price of $164.44 and a two-hundred day moving average price of $159.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $425.39 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.27 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.